JP2008507255A - ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０ - Google Patents

ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０ Download PDF

Info

Publication number
JP2008507255A
JP2008507255A JP2007503099A JP2007503099A JP2008507255A JP 2008507255 A JP2008507255 A JP 2008507255A JP 2007503099 A JP2007503099 A JP 2007503099A JP 2007503099 A JP2007503099 A JP 2007503099A JP 2008507255 A JP2008507255 A JP 2008507255A
Authority
JP
Japan
Prior art keywords
substituted
antibody
amino acid
acid sequence
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007503099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507255A5 (enExample
Inventor
ビクター ロシュケ，
クレイグ エー． ローゼン，
ルーベン，　スティーブン　エム．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of JP2008507255A publication Critical patent/JP2008507255A/ja
Publication of JP2008507255A5 publication Critical patent/JP2008507255A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
JP2007503099A 2004-03-12 2005-03-11 ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０ Withdrawn JP2008507255A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55218404P 2004-03-12 2004-03-12
PCT/US2005/008377 WO2005105841A2 (en) 2004-03-12 2005-03-11 Human g-protein chemokine receptor (ccr5) hdgnr10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008085005A Division JP2008259504A (ja) 2004-03-12 2008-03-27 ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０

Publications (2)

Publication Number Publication Date
JP2008507255A true JP2008507255A (ja) 2008-03-13
JP2008507255A5 JP2008507255A5 (enExample) 2008-05-01

Family

ID=35242258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007503099A Withdrawn JP2008507255A (ja) 2004-03-12 2005-03-11 ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
JP2008085005A Withdrawn JP2008259504A (ja) 2004-03-12 2008-03-27 ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008085005A Withdrawn JP2008259504A (ja) 2004-03-12 2008-03-27 ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０

Country Status (5)

Country Link
US (1) US7501123B2 (enExample)
EP (1) EP1723178A4 (enExample)
JP (2) JP2008507255A (enExample)
CA (1) CA2559809A1 (enExample)
WO (1) WO2005105841A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151719A1 (en) * 1995-06-06 2004-08-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US6261763B1 (en) * 1995-06-07 2001-07-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
CA2664752A1 (en) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
CA2719550A1 (en) * 2007-06-01 2008-12-11 Cytonics Corporation Methods and kits for diagnosing and treating acute joint injury
WO2009042773A1 (en) * 2007-09-25 2009-04-02 University Of Miami Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons
US20100233714A1 (en) * 2007-11-13 2010-09-16 Beadling Leslie C Multistate affinity ligands for the separation and purification of antibodies, antibody fragments and conjugates of
WO2009102473A2 (en) * 2008-02-14 2009-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
DE112009000608B4 (de) 2008-04-18 2017-12-28 Denso Corporation Kälteerzeugungszyklusvorrichtung eines Ejektor-Typs
WO2010028797A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028795A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010045024A1 (en) 2008-10-16 2010-04-22 Cytonics Corporation Biomarkers and methods for detecting and treating spinal and joint pain
EP2425001A4 (en) 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
US9169328B2 (en) 2010-03-26 2015-10-27 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN101914135B (zh) * 2010-07-23 2013-06-12 暨南大学 一种广谱趋化因子受体拮抗性多肽及其应用
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
WO2014037811A2 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
US20140087463A1 (en) * 2012-09-25 2014-03-27 The Washington University Optical control of cell signaling
US20160333100A1 (en) * 2013-12-20 2016-11-17 The University Of Bristol Conjugates for treating inflammatory disease and identification of patients likely to benefit from such treatment
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
CN116327922A (zh) * 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
DK3377894T3 (da) * 2015-11-20 2020-03-23 Treat4Life Ab Fremgangsmåde til lægemiddel-bindingsanalyse i en vævsprøve
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN114075286A (zh) * 2020-08-21 2022-02-22 张家港博泽利斯生物技术有限公司 一种抗人cxcr1蛋白单克隆抗体的制备方法

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
ES2250964T3 (es) 1992-11-10 2006-04-16 Genentech, Inc. Receptor de la quimioquina c-c(c-c ckr-1).
ATE164884T1 (de) 1992-11-17 1998-04-15 Icos Corp Neue sieben-transmembran-rezeptor v28
US5652133A (en) * 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
ATE157351T1 (de) 1993-02-20 1997-09-15 Hoechst Ag Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament, als inhibitoren des zellulären na+/h+-austauschs oder als diagnostikum sowie sie enthaltendes medikament
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
DE4408212A1 (de) 1994-03-11 1995-09-14 Bayer Ag 5-Vinyl- und 5-Ethinyl-chinolon- und -naphthyridon-carbonsäuren
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
AU2766395A (en) * 1995-06-05 1996-12-24 Human Genome Sciences, Inc. Human g-protein receptor hgber32
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) * 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
AU2663295A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Human g-protein chemokine receptor hdgnr10
US7265201B1 (en) 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997019696A1 (en) 1995-11-30 1997-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer C-c chemokines that inhibit retrovirus infection
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) * 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997025340A1 (en) 1996-01-11 1997-07-17 Human Genome Sciences, Inc. Human g-protein chemokine receptor hsatu68
EP0854918A1 (en) 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
EP0883687B1 (en) * 1996-03-01 2004-10-27 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
WO1997035881A2 (en) 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
EP0915969A4 (en) 1996-04-02 2002-04-17 Progenics Pharm Inc SUPPRESSION OF CD4 + CELL INFECTION BY HIV
EP0906424A2 (en) 1996-04-26 1999-04-07 Incyte Pharmaceuticals, Inc. Mammalian mixed lymphocyte receptors, chemokine receptors mmlr-ccr]
DE59712567D1 (en) 1996-04-30 2006-04-13 Pharis Biotec Gmbh Chemokine vom cc-typ
US6258527B1 (en) * 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
ES2270461T3 (es) 1996-06-03 2007-04-01 United Biomedical, Inc. Anticuerpos contra un complejo de cd4 y un dominio receptor de quemoquina, y sus usos contra las infecciones de vih.
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP4183754B2 (ja) 1996-06-14 2008-11-19 プロジェニクス・ファーマスーティカルス・インコーポレーテッド Ｈｉｖ―１感染を阻害するためのケモカイン受容体の使用
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1997049424A1 (en) 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1998000535A2 (en) 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
US5928881A (en) * 1996-07-11 1999-07-27 Smithkline Beecham Corporation Method of identifying agonists and antagonist for CC-CKR5 receptor
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
WO1998005798A1 (en) 1996-08-08 1998-02-12 The Aaron Diamond Aids Research Center Hiv coreceptor mutants
ATE360689T1 (de) 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
EP0956290A1 (en) 1996-10-09 1999-11-17 Dana-Farber Cancer Institute Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
US5939538A (en) 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
EP0954612A2 (en) 1996-11-06 1999-11-10 Sequenom, Inc. Dna diagnostics based on mass spectrometry
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AR011057A1 (es) 1997-01-08 2000-08-02 Smithkline Beecham Corp Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos
US5798206A (en) * 1997-01-10 1998-08-25 New York Blood Center Methods for screening of test compounds for inhibiting binding of a CD4-HIV 1 complex to a chemokine receptor
JP2001508798A (ja) 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
RU2126048C1 (ru) 1997-01-28 1999-02-10 Институт молекулярной генетики РАН Способ определения генетической устойчивости обследуемых к инфицированию вирусом иммунодефицита человека первого типа (вич-1)
WO1998034945A1 (en) 1997-02-06 1998-08-13 Epoch Pharmaceuticals, Inc. Targeted modification of the ccr-5 gene
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
AU6589698A (en) 1997-03-28 1998-10-22 Epitope, Inc. Simultaneous collection of dna and non-nucleic analytes from oral fluids
IT1291353B1 (it) 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
FR2764387B1 (fr) 1997-06-05 1999-07-23 Centre Nat Rech Scient Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand
EP0989802A1 (en) 1997-06-23 2000-04-05 J. David Gladstone Institutes Transgenic rabbits expressing cd4 and chemokine receptor
AU3044697A (en) 1997-06-24 1999-01-04 Norman Godin A composition for specific immunoprotection and method for obtaining said comp osition
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AU8669598A (en) 1997-07-29 1999-02-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine receptor ccr8 dna and uses thereof
US6019979A (en) 1997-08-15 2000-02-01 The Picower Institute For Medical Research Anti-viral treatment with pertussis toxin B oligomer
CA2298813A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
AU9495098A (en) 1997-09-19 1999-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for use of interleukin 4 (il-4) to treat human immunodeficiency virus infection
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
AU1120799A (en) 1997-10-30 1999-05-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Stromal cell derived factor-1 (sdf-1) and method of use for diagnostic and prognostic indicator of aids pathogenesis
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc MODIFICATION OF VIRUSTROPISMIUS AND THE ECONOMIC SPECTRUM BY VIRAL GENOM MIXING
WO1999024065A1 (en) 1997-11-10 1999-05-20 The Trustees Of Columbia University In The City Of New York COMPOUNDS INHIBITING CD4-gp120 INTERACTION AND USES THEREOF
WO1999024553A2 (en) 1997-11-10 1999-05-20 The Trustees Of Columbia University In The City Of New York X-ray crystal comprising hiv-1 gp120
FR2771423A1 (fr) 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
AU1616499A (en) 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
WO1999027939A1 (en) 1997-12-04 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
JP2001526241A (ja) 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
ATE308616T1 (de) 1997-12-23 2005-11-15 San Raffaele Centro Fond Rantes mutanten und deren therapeutische verwendungen
CA2317895A1 (en) 1998-01-15 1999-07-22 Btg International Limited Ribozymal nucleic acids cleaving ccr5 or cxcr4
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP1056778B1 (en) 1998-02-27 2007-12-26 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services G protein-coupled receptor antagonists
JPH11243960A (ja) 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトｃｃ型ケモカインエオタキシン３
US6100087A (en) 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
US6287805B1 (en) * 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
JPH11292795A (ja) 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
AU3644499A (en) 1998-04-16 1999-11-01 Vanderbilt University Methods and compositions for high yield production of eukaryotic proteins
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO1999067429A1 (en) 1998-06-23 1999-12-29 Uab Research Foundation Cell-based assay for immunodeficiency virus infectivity and sensitivity
DE69905291T3 (de) 1998-07-06 2009-06-25 Perkinelmer Cellular Sciences Belgium Sprl Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
HUP0102752A3 (en) 1998-07-28 2002-11-28 Smithkline Beecham Corp Substituted anilide compounds
CA2338697A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
JP2002521441A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ｃｃｒ５モジュレーターとしてのプロペンアミド
EP0979655A1 (de) 1998-08-01 2000-02-16 Boehringer Mannheim Gmbh Mittel zur Behandlung von durch RNA-Viren, wie beispielsweise HIV verursachten Infenktionen
WO2000008043A2 (en) 1998-08-03 2000-02-17 The University Of Montana Prevention and treatment of viral disease
CA2333901A1 (en) 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
DK1112362T3 (da) 1998-09-10 2006-06-19 Eurofins Medigenomix Gmbh Genforandring i genet for G$g(b)3-underenheden i det menneskelige G-protein
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
AU2001243145A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
JP4715074B2 (ja) 2000-02-29 2011-07-06 ダイキン工業株式会社 テトラフルオロエチレンの製造方法
CA2412223A1 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US7005503B2 (en) * 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7393934B2 (en) * 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
MXPA04008798A (es) 2002-03-12 2004-11-26 Maxygen Aps Moleculas semejantes a interferon beta para el tratamiento de evento cerebrovascular.
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer

Also Published As

Publication number Publication date
WO2005105841A3 (en) 2006-04-20
JP2008259504A (ja) 2008-10-30
CA2559809A1 (en) 2005-11-10
US7501123B2 (en) 2009-03-10
WO2005105841A2 (en) 2005-11-10
EP1723178A2 (en) 2006-11-22
US20070122405A1 (en) 2007-05-31
EP1723178A4 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
US7862818B2 (en) Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
CN1227265C (zh) 抗ccr5的抗体
US20090047735A1 (en) Antibodies Against Human G-Protein Chemokine Receptor (CCR5) HDGNR10
AU2002250032B2 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
US20020172660A1 (en) Human interferon-epsilon: a type I interferon
AU2002250032A1 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
JP2004500080A (ja) １７個のヒト分泌タンパク質
WO2009102473A2 (en) Human g-protein chemokine receptor (ccr5) hdgnr10
JP2003528580A (ja) ヒトニューロペプチドレセプター
AU2008209670A1 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
ES2359629T3 (es) Receptor de quimiocina de proteína g(ccr5) humano hdgnr10 receptor de quimiocina de proteína g (ccr5) humano hdgnr10 receptor de quimiocina de proteína g (ccr5) humano hdgnr10 receptor de quimiocina de proteína g (ccr5) humano hdgnr10.
JP2003514517A (ja) ヒトケモカインβ−１３
JP2002534112A (ja) 骨髄特異的タンパク質
JP2003516164A (ja) Ｔ１レセプター様リガンドｉｉおよびこれの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080311

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090626